Protagenic Therapeutics, Inc.\new
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $901.9K | $376.7K | $3.8M | $3.1M | $1.6M | $1.1M | $699.8K | $417.9K |
| SG&A Expense | $332.4K | $77.5K | $1.8M | $1.2M | $2.0M | $3.0M | $1.9M | $1.4M |
| Operating Income | $-4.5M | $-2.6M | $-5.7M | $-4.5M | $-3.6M | $-4.1M | $-2.6M | $-2.2M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | $107.7K | $137.5K | $496.9K | $246.2K | $7.2K |
| Pretax Income | $1.4M | $-3.6M | $-5.5M | $-5.0M | $-3.6M | $-4.5M | $-2.5M | $-2.3M |
| Income Tax Expense | — | — | — | — | — | — | — | $0 |
| Net Income | $1.4M | $-3.6M | $-5.5M | $-5.0M | $-3.6M | $-4.5M | $-2.5M | $-2.3M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $0.59 | $-0.67 | $-1.13 | $-1.15 | $-0.82 | $-1.24 | $-0.25 | $-0.43 |
| EPS (Diluted) | $0.59 | $-0.67 | $-1.13 | $-1.15 | $-0.82 | $-0.31 | $-0.25 | $-0.43 |
| Shares Outstanding (Basic) | 2.3M | 5.4M | 4.9M | 4.3M | 4.3M | 3.7M | 10.4M | 10.3M |
| Shares Outstanding (Diluted) | 2.3M | 5.4M | 4.9M | 4.3M | 4.3M | 3.7M | 10.4M | 10.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |